The Regulatory Driver: How an Enhancer Variant Shapes Nicotine Addiction Risk
Most genetic research on nicotine dependence has focused on a single amino acid change
in the CHRNA5 gene (rs16969968, D398N), but the 15q25.1 locus harbors a second distinct
mechanism: a cis-regulatory variant that controls how much CHRNA3 and CHRNA5 are made
in the first place. rs2036527 sits approximately 511 base pairs upstream of CHRNA5 |
Located in an intergenic enhancer between PSMA4 and CHRNA5, this variant was long
assumed to be a proxy for rs16969968 but recent functional work shows it acts
independently in a regulatory element that
loops to the CHRNA3 promoter and simultaneously influences CHRNA5 expression. The A
allele is the risk form — it reduces enhancer activity and perturbs the output of both
nicotinic receptor genes in concert.
rs2036527 is especially important for people of African ancestry. In Europeans the
closely related coding variant rs16969968 is common (~35% minor allele frequency) and
dominates association signals; in African Americans rs16969968 is nearly absent, yet
15q25.1 still strongly predicts smoking behavior. The African ancestry GWAS meta-analysis
spanning 32,389 individuals | Study of Tobacco in Minority Populations Genetics
Consortium across 13 cohorts found rs2036527
to be the top genome-wide significant hit for cigarettes per day in this population
(P=1.84×10⁻⁸), meaning it captures an independent regulatory signal that the
rs16969968-centred haplotype misses entirely in non-European cohorts.
The Mechanism
The CHRNA5 gene and the adjacent CHRNA3 gene encode the α5 and α3 subunits of the
nicotinic acetylcholine receptor (nAChR), the brain's principal sensor for nicotine.
rs2036527 lies within a chromatin domain that physically loops to contact the CHRNA3
promoter — a long-range regulatory interaction confirmed by 3C (chromosome conformation
capture) assay | 3C quantifies how often two genomic segments touch, which indicates
functional regulatory contact. The risk-A
allele alters the binding site for the transcription factor FOXA2 (forkhead box A2) |
FOXA2 is a pioneer transcription factor that opens chromatin and recruits other
activators, reducing enhancer activity
as demonstrated by luciferase reporter assay. Because the same enhancer loops to both
CHRNA3 and CHRNA5, impaired FOXA2 binding suppresses expression of both receptor
subunits simultaneously.
This regulatory mechanism is distinct from, and partially independent of, the D398N
amino acid variant in rs16969968. In Europeans the two signals are in high LD (r²≈0.93),
making it difficult to separate their contributions. In African Americans, where rs16969968
is nearly monomorphic (minor allele frequency ~2%), rs2036527 acts as the sole carrier
of genetic risk at this locus — demonstrating its independent causal role.
The Evidence
The regulatory function of rs2036527 was established by Peng et al. 2025 | Peng et al.
Identification of rs2036527 as a cis-regulatory variant for CHRNA3 and CHRNA5. Am J
Addictions, 2025, who combined allele-specific
expression analysis, chromatin conformation capture, luciferase assay, and expression
quantitative trait locus (eQTL) validation to pin the mechanistic responsibility on
rs2036527 rather than on surrounding proxy variants.
For smoking behavior, the STOMP Genetics Consortium meta-analysis | Study of Tobacco in
Minority Populations Genetics Consortium, pooling data from 13 studies
found that each copy of the A allele increases cigarettes smoked per day by approximately
one cigarette (β=0.040 in log-CPD units). Mean daily consumption by genotype was 14.6
cigarettes for AA, 13.5 for AG, and 12.8 for GG, demonstrating a clean additive gradient.
For lung cancer, a GWAS in 4,702 African American cases and controls | Confirmed
15q25.1 as a lung cancer locus in this population
found rs2036527 associated with risk (OR=1.32, 95% CI 1.20–1.44, P=1.3×10⁻⁹). An
earlier case-control study reported OR=1.67 (95% CI 1.26–2.21) in African Americans,
and even among never-smokers rs2036527 remained associated with lung cancer risk
(OR=1.58, 95% CI 1.12–2.26, P=9.9×10⁻³), suggesting both behavioral and potentially
direct tissue effects.
Cessation pharmacotherapy outcomes also vary by genotype. A pharmacogenomics study in
1,295 African-American smokers randomized to nicotine gum or bupropion | Randomized
clinical trial design; one of the few cessation pharmacogenomics studies in an African
American population found that A allele
carriers had substantially lower abstinence rates with active pharmacotherapy during
treatment (OR=0.42, P<0.001) and at end of treatment (OR=0.55, P=0.004). The effect
was most pronounced for nicotine gum (OR=0.31, P<0.001 during treatment).
Interestingly, a complementary study found that in women, the GA and AA genotypes were
associated with higher cessation success rates | 41.5% and 56.5% for GA and AA vs 34.8%
for GG in women, suggesting sex and
treatment context modulate the genotype effect.
Practical Actions
The A allele weakens expression of nicotinic receptor subunits, blunting the normal
aversive response to high nicotine doses that acts as a brake on heavy smoking. The
consequence is the same as for rs16969968 carriers — easier escalation to heavy smoking,
harder cessation — but the molecular route is different (gene expression rather than
receptor function). In non-European populations where rs16969968 is rare, rs2036527
provides the actionable genetic signal.
Awareness of the genotype is most useful for (a) pre-smoking risk counseling, (b)
selecting cessation pharmacotherapy, and (c) lung cancer surveillance planning. Nicotine
replacement monotherapy appears less effective for A allele carriers; agents acting on
nAChRs by a different route — specifically varenicline — are preferable. Lung cancer
screening discussions should incorporate this variant, especially in individuals with any
smoking history.
Interactions
In European populations, rs2036527 is in substantial LD (r²≈0.93) with the nonsynonymous
CHRNA5 variant rs16969968 and near-complete LD with the CHRNA3 synonymous variant
rs1051730, meaning all three variants are usually inherited together. A person whose
genome includes both rs16969968(A) and rs2036527(A) carries a compounded mechanism:
impaired receptor function (D398N structural change) plus reduced receptor gene
expression (enhancer disruption). In African and other non-European populations, the LD
breaks down (r²=0.44–0.50 with rs1051730 in African ancestry; rs16969968 nearly absent),
making rs2036527 the primary causal variant — and the only variant providing meaningful
genetic risk information at this locus for most people outside European ancestry.
The 15q25.1 locus has also been associated with risk for schizophrenia and bipolar
disorder through variants in strong LD with rs1051730, suggesting that nicotinic receptor
expression regulated by this enhancer cluster may influence broader neuropsychiatric
vulnerability beyond tobacco dependence.
All Genotypes
Common genotype; normal CHRNA3 and CHRNA5 enhancer activity, standard nicotine addiction risk
You carry two copies of the G allele at rs2036527, meaning the FOXA2-binding enhancer at 15q25.1 functions normally and drives typical expression levels of CHRNA3 and CHRNA5. About 61% of people globally share this genotype. Your nicotinic aversion circuit is intact — you are likely to experience the full spectrum of aversive effects (nausea, dizziness, increased heart rate) that naturally limit nicotine intake and escalation. If you do smoke, standard cessation approaches are expected to work well for you, and you do not carry the additional regulatory disadvantage that A allele carriers face. Note that other variants at this locus (particularly rs16969968 in European populations) provide separate and partially independent risk information.
One copy of the risk allele; moderately reduced nicotinic receptor expression and moderately elevated addiction risk
You carry one copy of the A allele at rs2036527, partially reducing enhancer-driven expression of CHRNA3 and CHRNA5. About 34% of people globally share this heterozygous genotype. You have a partial impairment in the aversion circuit that limits nicotine intake, making escalation to heavier smoking moderately more likely than for GG carriers and cessation moderately harder. In African-ancestry populations this heterozygous state represents the most common risk-carrying genotype at this locus. Lung cancer risk is modestly elevated compared to GG carriers (approximately 1.3-fold based on the additive OR of ~1.32 per allele copy).
Both copies of the risk allele; substantially reduced nicotinic receptor gene expression and elevated addiction and lung cancer risk
You carry two copies of the A allele at rs2036527, which significantly reduces the activity of an enhancer that drives expression of the CHRNA3 and CHRNA5 nicotinic receptor genes. This means your brain produces less of the alpha-3 and alpha-5 receptor subunits that form part of the aversion circuit normally limiting nicotine intake. About 5% of people of mixed global ancestry share this genotype; it is more common (~5%) in African-ancestry populations given the higher A allele frequency (~22%) there. This is the highest-risk genotype for nicotine dependence via the regulatory pathway at 15q25.1 — if you are of non-European ancestry, this variant is likely your primary genetic signal for nicotine addiction risk, as the related coding variant rs16969968 is rare in your population. Lung cancer risk is elevated approximately 1.6–1.7-fold compared to GG carriers, an effect that persists partly independent of smoking behavior.